The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .
Plasma lycopene, other carotenoids, and the risk of type 2 diabetes in women.
The authors conducted a nested case-control study from 1992 to 2003 among US women aged 45 years or older and free from cardiovascular disease and cancer to examine the prospect i ve association among plasma lycopene , other carotenoids , and the risk of developing type 2 diabetes . During 10 years of follow-up , 470 cases of incident type 2 diabetes were selected and individually matched on age ( + /- 1 year ) and follow-up time to 470 nondiabetic controls .  Baseline plasma levels of lycopene , alpha-carotene , beta-carotene , beta-cryptoxanthin , and lutein/zeaxanthin  were similar in cases and controls ( all p > 0.05 ) . A possible crude inverse association between plasma lycopene and risk of type 2 diabetes was attenuated upon multivariate adjustment . After control for plasma total cholesterol and known diabetes risk factors , the multivariate odds ratios of type 2 diabetes in the highest versus the lowest quartile of plasma carotenoids were 1.13 ( 95 % confidence interval ( CI ) : 0.60 , 2.13 ) for lycopene , 1.27 ( 95 % CI : 0.63 , 2.57 ) for alpha-carotene , 1.10 ( 95 % CI : 0.57 , 2.13 ) for beta-carotene , 0.91 ( 95 % CI : 0.46 , 1.81 ) for beta-cryptoxanthin , and 1.35 ( 95 % CI : 0.68 , 2.69 ) for lutein/zeaxanthin . There was no prospect i ve association between baseline plasma carotenoids and the risk of type 2 diabetes in middle-aged and older women
The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .